Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation-Reference-Cited by-同舟云学术

Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation

Published:2013-07-09 Issue:5 Volume:162 Page:639-647
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Vose Julie M.¹,Habermann Thomas M.²,Czuczman Myron S.³,Zinzani Pier Luigi⁴,Reeder Craig B.⁵,Tuscano Joseph M.⁶,Lossos Izidore S.⁷,Li Ju⁸,Pietronigro Dennis⁸,Witzig Thomas E.²

Affiliation:

1. University of Nebraska Medical Center; Omaha; NE; USA

2. Mayo Clinic; Rochester; MN; USA

3. Roswell Park Cancer Institute; Buffalo; NY; USA

4. Institute of Haematology and Oncology Seragnoli; University of Bologna; Bologna; Italy

5. Mayo Clinic Arizona; Scottsdale; AZ; USA

6. UC Davis Comprehensive Cancer Center; Sacramento; CA; USA

7. University of Miami School of Medicine; Miami; FL; USA

8. Celgene Corporation; Summit; NJ; USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12449/fullpdf

Reference40 articles.

1. Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation;Calvo-Villas;Annals of Oncology,2010

2. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;Journal of Clinical Oncology,1999

3. Long-term outcome of patients in the LNH-98·5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

4. Hematopoietic stem-cell transplantation;Copelan;New England Journal of Medicine,2006

5. Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana;Czuczman;Clinical Advances in Hematology and Oncology,2010

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety Profile of Lenalidomide vs Lenalidomide + R-CHOP in patients with Diffuse Large B Cell Lymphoma: A Systematic Review;Pakistan Journal of Health Sciences;2023-08-31

2. A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma;Hematology;2023-05-03

3. Lenalidomide maintenance following high‐dose therapy and autologous haematopoietic stem cell transplantation in chemo‐resistant or high‐risk non‐Hodgkin lymphoma: A phase I/II study;British Journal of Haematology;2023-04-25

4. Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a meta-analysis of randomized controlled trials;Clinical and Experimental Medicine;2022-10-31

5. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes;Clinical Lymphoma Myeloma and Leukemia;2022-01